Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Trileptal 60 mg/ml Oral Suspension
Medicines register · Ireland

Trileptal 60 mg/ml Oral Suspension

Authorisation PA0896/033/004 · Novartis Ireland Limited

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 21 Nov 2026
Licence holder
Novartis Ireland Limited (all products →)
Active substance
Oxcarbazepine
Dosage form
Oral suspension
Route of administration
Oral use
ATC codes
N03AF, N03AF02
First authorised
18/02/2000
Prescription status
Product subject to prescription which may be renewed (B)
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

Oxcarbazepine: supply and approvals

11 authorised products on the HPRA list contain Oxcarbazepine. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 20 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 20 Nov 2026)
Germany (BfArM)
1 supply notice, e.g. Oxcarbazepin - 1 A Pharma 60 mg/ml Suspension zum Einnehmen (9 May 2025 to 30 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 26 years (since 18 February 2000). The HPRA list marks it as marketed in Ireland.

Other medicines with Oxcarbazepine in Ireland

10 other products on the HPRA list contain Oxcarbazepine, from 4 licence holders; 3 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Trileptal 150 mg Film-coated tabletsNovartis Ireland LimitedNational authorisation (PA)Marketed
Trileptal 300 mg Film-coated tabletsNovartis Ireland LimitedNational authorisation (PA)Marketed
Trileptal 600 mg Film-coated tabletsNovartis Ireland LimitedNational authorisation (PA)Marketed
Trileptal 300 mg film-coated tabletsPCO Manufacturing Ltd.Parallel import (PPA)Not stated
Trileptal 300 mg film-coated tabletsIMED Healthcare Ltd.,Parallel import (PPA)Not stated
Trileptal 60 mg/ml Oral SuspensionOriginalis B.V.Parallel import (PPA)Not stated
Trileptal 60 mg/ml Oral SuspensionIMED Healthcare Ltd.,Parallel import (PPA)Not stated
Trileptal 60 mg/ml oral suspensionPCO Manufacturing Ltd.Parallel import (PPA)Not stated
Trileptal 600 mg film-coated tabletsPCO Manufacturing Ltd.Parallel import (PPA)Not stated
Trileptal 600 mg film-coated tabletsIMED Healthcare Ltd.,Parallel import (PPA)Not stated

Other substances in ATC group N03AF

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 3 other active substances share the group N03AF with this product:

Carbamazepine (7) · Eslicarbazepine acetate (5) · Rufinamide (2)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Novartis Ireland Limited holds 46 products on the HPRA list, with 17 different active substances; 41 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.